Latest Applied genetics Stories
Researchers in Latvia and Finland have synthesized and studied a range of organic compounds able to carry genetic material into individual cells where it can remedy the diseases caused by defective genes.
FORT LEE, N.J., June 22 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease (PD), NLX-P101.
AMSTERDAM, May 19, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive.
PARIS, May 11 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, has been invited to present Cellectis' approaches on vectors for meganucleases and genome surgery at the 13th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting to be held at the Marriott Wardman Park Hotel in Washington, USA, on May 19-22, 2010. Targeted approaches have emerged today as an...
Novel therapy for blindness works only when specific gene mutation present.
AMSTERDAM, March 10, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease. The trial is an open label dose-escalation study using a vector-gene combination developed at the renowned St.
Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle.
AMSTERDAM, The Netherlands, January 25 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, has reached another important milestone in the official marketing authorisation process for its lead product Glybera(R), AMT's proprietary product for lipoprotein lipase deficiency (LPLD).
Tag-team Approach Breaks the Size Barrier for Gene Therapy.
- The act of sweetening by admixture of some saccharine substance.